Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus WIXELA INHUB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus WIXELA INHUB.
BREO ELLIPTA vs WIXELA INHUB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Wixela Inhub is an inhaled corticosteroid (fluticasone propionate) and long-acting beta2-adrenergic agonist (salmeterol) combination. Fluticasone propionate reduces inflammation by binding to glucocorticoid receptors, inhibiting pro-inflammatory mediators. Salmeterol stimulates beta2-receptors in bronchial smooth muscle, leading to bronchodilation via activation of adenylate cyclase and increased cAMP.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
2 inhalations (total dose 50 mcg indacaterol/110 mcg glycopyrrolate) once daily via oral inhalation.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged (up to 30-50 hours) in renal impairment.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily renal excretion (70-80%) as unchanged drug; biliary/fecal (20-30%) as parent and metabolites.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid/LABA Combination